liprotamase

Liprotamase is an orally administered, non‐porcine, microbially derived pancreatic enzyme replacement therapy (PERT) developed for the treatment of exocrine pancreatic insufficiency (EPI), particularly in patients with cystic fibrosis, chronic pancreatitis, or following pancreatectomy[1][3][4][5]. It consists of a fixed ratio of three active enzymes—crystalline lipase, crystalline protease, and amorphous amylase—designed to improve the absorption of fats, proteins, and carbohydrates respectively[5]. Unlike traditional PERTs derived from porcine sources, liprotamase is biotechnology-derived and offers an alternative for patients unable to use animal-based products[1][3]. The drug was originally developed by Cystic Fibrosis Foundation Therapeutics and further advanced by Anthera Pharmaceuticals and Alkira Therapeutics[4]. Despite promising results in phase III clinical trials demonstrating improved fat and protein absorption with good tolerability in cystic fibrosis patients with EPI[7][8], development was discontinued after regulatory setbacks.

Brand names

TrizytekSollpuraTheraCLEC-Total

Other names

Liprotamase proteaseA. melleus proteaseAspergillus melleus proteasePromelaseProtease-SSeaprose-S